

# Liver Cancer: The Silent Killer

Hepatitis B Patient Forum, September 20 2025

Robert Mitchell, MD  
Gastroenterology, Surrey Memorial Hospital  
Clinical Assistant Professor, UBC




## Disclosure

- No financial disclosures relevant to this talk





## Case

- 65 year-old man
- Past Medical History: Chronic Hepatitis B infection
- Diagnosed with Hepatitis B many years ago, has been aware of the diagnosis, but has not had a regular family doctor, or follow up in over 5 years.
- Presents to hospital with abdominal pain
- An ultrasound is performed





# Ultrasound






## Liver cancer is a leading cause of worldwide cancer death



Sung et al; GLOBOCAN 2020 Cancer stats




## Worldwide distribution of liver cancer varies and is more common in regions with increased Hepatitis B infection



Llovet et al Nat Rev Dis Primers 2019  
AASLD 2023 HCC guidelines

## Who is at high risk for liver cancer?

- General population risk of liver cancer (without underlying liver disease) is very low
- Increased risk in patients with **advanced fibrosis/cirrhosis** from any cause (alcohol, hepatitis C, etc)
- Increased risk in patients with **chronic hepatitis B (Surface Antigen Positive)** infection, **even without cirrhosis**



## Taking antiviral therapies for hepatitis B reduces the risk of liver cancer

- Taking hepatitis B antiviral therapy has a pooled liver cancer risk reduction of ~30% in non-cirrhotic patients
- Taking hepatitis B antiviral has a pooled liver cancer risk reduction of ~80% in patients with cirrhosis
- **Even if you are taking antiviral, the risk of liver cancer is high enough that screening should be considered in some situations**








## Who is at high risk for liver cancer?

Population group	Incidence of HCC
Sufficient risk to warrant surveillance	
Child-Pugh A–B cirrhosis, any etiology	≥ 1.0% per year
Hepatitis B	
Hepatitis C (viremic or post-SVR)	
Alcohol associated cirrhosis	
Nonalcoholic steatohepatitis	
Other etiologies	
Child-Pugh C cirrhosis, transplant candidate	
Non-cirrhotic chronic hepatitis B	≥ 0.2% per year
Man from endemic country	
age > 40 y	
Woman from endemic country	
age > 50 y	
Person from Africa at earlier age	
Family history of HCC	
Insufficient risk and in need of risk stratification models/biomarkers	
Hepatitis C and stage 3 fibrosis	< 0.2% per year
Noncirrhotic NAFLD	

## How to screen for liver cancer in at risk patients? Using an ultrasound and labs every 6 months




## A blood test called Alpha Fetoprotein (AFP) may be added onto ultrasound increase screening sensitivity



Tzarteva et al.; Gastroenterology 2018  
AASLD 2023 HCC Guidelines


## There are some limitations with ultrasound as a screening test for liver cancer




Simmons et al.; Aliment Pharmacol Ther 2017




## There are some limitations with ultrasound as a screening test for liver cancer




Simmons et al.; Aliment Pharmacol Ther 2017




If ultrasound is of poor quality to see the liver, your doctor will order a CT scan or MRI to better visualize the liver. Sometimes this can detect subtle liver lumps not seen on ultrasound



Arterial Phase




Venous Phase




## Not every “liver lump” is liver cancer

- Common benign (non-cancer) lesions
  - Hepatic hemangioma (5- 20% of general population)
  - Focal nodular hyperplasia (0.4% - 3% of general population)
  - Hepatocellular adenoma (less than 0.004% of general population)
  - Liver cysts
  - “Focal” fat infiltration
- Common malignant (cancerous) lesions
  - Liver cancer
  - Bile duct cancer
  - Cancer from elsewhere spread to the liver




When a “liver lump” is found on ultrasound. Your doctor will order a CT scan or MRI to distinguish between liver cancer and benign liver spots. Usually this will give an answer without needing a biopsy.




Arterial (20 - 30 sec)	Portal venous (60 - 80 sec)	Delayed (6 - 10 min)
<p>Hypervascular metastasis Hypovascular metastasis</p>		
<p>HCC</p>		



Following the CT scan or MRI, your doctor may present your case at a Multidisciplinary Liver Tumor Board for a detailed review and discussion where a “risk score” will be assigned to the liver lump



Li-RADS (risk score) is an effective way for doctors to categorize and communicate the risk of certain liver lumps being cancer



Van der Pol et al, Gastroenterology 2019


## If uncertainty remains about the nature of liver lump after CT or MRI and a discussion at Multidisciplinary Liver Tumor Board, your doctor may order a liver biopsy

- Routine biopsy of suspected liver cancer is usually not done because liver cancer has a very specific and unique appearance on CT or MRI
- Biopsy of liver lumps is only done if there is true uncertainty about the nature of the liver lump following appropriate imaging with CT or MRI and a discussion at Liver Tumor Board
- Liver biopsy is generally very safe, but every procedure comes with small risks (bleeding, injury to other organs, spreading tumor cells through the liver)



## The “staging” of liver cancer considers aspects of the tumor, liver and patient


- Size of the liver tumors
- Number of liver tumors
- Spread of the tumors into blood vessels or outside of the liver (metastasis)
- Liver function
- Overall patient wellness and health







## Treatment of liver cancer is complex, and individualized, but might include:

- **Surgery** -- Cutting out the tumor




## Treatment of liver cancer is complex, and individualized, but might include:

- Surgery
- **Ablation** -- Treating the tumor with high energy microwave probe or heating probe




## Treatment of liver cancer is complex, and individualized, but might include:

- Surgery
- Ablation
- **Embolization** -- Starving the blood supply to the liver using chemotherapy or radiation coated synthetic “blood-clots” or beads



## Treatment of liver cancer is complex, and individualized, but might include:


- Surgery
- Ablation
- Embolization
- **Radiation** -- Targeted radiation applied from the outside of the body directly to the tumor






## Treatment of liver cancer is complex, and individualized, but might include:

- Surgery
- Ablation
- Embolization
- Radiation
- **Chemotherapy/Immunotherapy** -- Medicines given by IV that destroy tumor cells inside the liver and elsewhere in the body




## Treatment of liver cancer is complex, and individualized, but might include:

- Surgery
- Ablation
- Embolization
- Radiation
- Chemotherapy/Immunotherapy
- **Liver transplant** -- Surgically remove unhealthy liver containing tumors, and place new healthy liver from a donor



In practice, many of these therapies occur in sequence over time through complex care pathways and algorithms





## Case

- 65 year-old man
- Past Medical History: Chronic Hepatitis B infection
- Diagnosed with Hepatitis B many years ago, has been aware of the diagnosis, but has not had a regular family doctor, or follow up in over 5 years.
- Presents to hospital with abdominal pain
- An ultrasound is performed







# Ultrasound



## CT Scan



Arterial Phase



Venous Phase



## Case Outcome

Case presented at tumor board. Defined goal at tumor rounds to downstage tumor to transplantation

- Started on Lenvatinib (**Medical Oncologist**) and monitored, minimal tumor growth after 6 months.
- Subsequently treated with a local radiation to tumor (Y-90) (**Interventional Radiologist**) with intent to downstage tumor
- Concurrent transplant work-up in background with hepatitis B treatment (**Hepatologist**)
- Short admission to hospital for dehydration and hyponatremia after Y-90 (**Internal Medicine Doctor**)
- Determined to be within transplant criteria following Y-90, and underwent liver transplant (**Hepatobiliary Surgeon, Transplant Doctor**)



## In Conclusion

- Liver cancer is deadly, and is often diagnosed too late, leading to a high rate of mortality in comparison with other cancers
- Chronic Hepatitis B infection (surface antigen positive) is a major risk factor for liver cancer, even if you do not have scarring/cirrhosis. Taking antiviral therapy significantly reduces this risk
- Persons with Hepatitis B infection should be screened with ultrasound and bloodtest (alpha fetoprotein) every 6 months
- If liver cancer is diagnosed, your doctor will review your case at a multidisciplinary tumor board with other doctors to decide on the best individualized treatment plan





**Thank you for your  
attention!**

